$50 offfirst month

Live coverage · July 23–24, 2026

PCAC peptide vote tracker

One clear view of the FDA webcast, the 14 Section 503A voting questions, and every verified result as it lands.

Updated July 23 after the TB-500 vote

Verified from FDA webcast and meeting documents

Results board

Seven peptides. Fourteen questions.

Favorable Pending

BPC-157

Day 1 · Free base + acetate

Favorable recommendation

Both form-level questions received the same favorable tally.

8
Yes
6
No
1
Abstain

KPV

Day 1 · Free base + acetate

Favorable recommendation

The committee delivered a favorable recommendation.

TB-500

Day 1 · Free base + acetate

Favorable recommendation

The committee delivered another favorable 8–6–1 result.

8
Yes
6
No
1
Abstain

MOTS-c

Day 1 · Free base + acetate

Awaiting result

Awaiting a verified form-level result.

Emideltide (DSIP)

Day 2 · Free base + acetate

Awaiting result

Scheduled for Friday morning.

Epitalon

Day 2 · Free base + acetate

Awaiting result

Scheduled for Friday morning.

Semax

Day 2 · Free base + acetate

Awaiting result

Scheduled for Friday afternoon.

What moved the room

Two records from the hearing

The testimony behind two of Thursday’s favorable recommendations.

16M+

More than 16 million doses, with seven complaints.

Dr. Alex Tatem presented aggregated BPC-157 use with no clear attributable adverse safety signal.

Watch the testimony
Complaints
7
Clear signal
None
190K

A case built on human context, real-world use, and FDA’s own searches.

Tatem connected full-length thymosin beta-4 trials, nearly 190,000 compounded vials, no serious complaints, and no human adverse-event cases found in FDA’s searches.

Watch Tatem’s case
Restoring Category 1 would move demand away from grey-market research products and under regulated compounding oversight.

What happens next

A favorable PCAC vote is a recommendation—not the final list update.

BPC-157, KPV, and TB-500 now move forward for FDA consideration. The federal process still has to update the Section 503A Bulks List.

Quick answers

The meeting, without the hunt.

New to PCAC? Read the plain-English explainer.

Where can I watch the PCAC live stream?

FDA is streaming the July 2026 PCAC meeting on YouTube. The July 23 and July 24 official webcasts are linked directly from this tracker.

Which peptides is PCAC voting on?

The July 2026 PCAC peptide agenda covers BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax in free-base and acetate forms.

What are the latest PCAC peptide vote results?

BPC-157 free base, BPC-157 acetate, KPV, and TB-500 received favorable committee results on July 23. This tracker keeps the remaining peptide votes together as they are reported.

What time does the July 24 PCAC meeting start?

The July 24 PCAC meeting starts at 8 a.m. Eastern and covers emideltide (DSIP), Epitalon, and Semax.

Can I watch a PCAC webcast replay?

Yes. The same official FDA YouTube links remain available for replay after each PCAC livestream ends.

What does PCAC stand for?

PCAC stands for Pharmacy Compounding Advisory Committee, the FDA advisory committee discussing the Section 503A Bulks List peptide nominations.

Coverage continues Friday

Keep the tracker open for Day 2.